A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected population of participants with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) (LEAP-010).
This Study is
No Longer Enrolling
Details
Age
Adult
Type of Study
Treatment
Locations
Highlands Ranch Hospital
University of Colorado Hospital
Study ID
Protocol Number: 19-2721
More information available at ClinicalTrials.gov: NCT04199104
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers